Sort by
Medicine and Dentistry
Ulcerative Colitis
86%
Crohn's Disease
82%
Inflammatory Bowel Disease
78%
Patient with Inflammatory Bowel Disease
49%
Chromoendoscopy
44%
Colorectal Cancer
35%
Disease
31%
Dysplasia
30%
Neoplasm
24%
Surgery
21%
Recurrent Disease
20%
Biopsy
19%
Colonoscopy
19%
Inflammatory Bowel Disease
18%
Colectomy
18%
Colitis
17%
Cohort Analysis
16%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Anal Fistula
16%
Symptom
15%
Ustekinumab
15%
Combination Therapy
15%
Systematic Review with Meta-Analysis
13%
Drug Therapy
13%
White Light Endoscopy
13%
Endoscopy
10%
Biological Therapy
9%
Drug Antibody
9%
Tertiary Care
9%
COVID-19 Vaccination
9%
Precursor
8%
Colon Mucosa
8%
Disease Course
8%
Disease Management
8%
Odds Ratio
8%
Meta-Analysis
7%
Surgeon
7%
Fistula
7%
Ileum
7%
Hazard Ratio
7%
TNF Inhibitor
7%
Colorectal Tumor
6%
Granulomatous Colitis
6%
Next Generation Sequencing
6%
Tumor Necrosis Factor Antibody
6%
Lung Nodule
6%
Antibody Therapy
6%
Intestine Surgery
6%
Autoimmune Disease
6%
Whole Genome Sequencing
6%
Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
65%
Ulcerative Colitis
36%
SARS-CoV-2 mRNA Vaccination
20%
Colorectal Cancer
19%
Inflammation
18%
Neoplasia
17%
Virtual Chromoendoscopy
16%
Histological Remission
16%
Ustekinumab
16%
Clinical Outcome Prediction
15%
Remission
14%
Dysplasia
14%
Colonoscopy
14%
Perianal Crohn's Disease
13%
Serrated Epithelial Change
13%
Case-controlled Study
13%
Systematic Meta-analysis
13%
Post-vaccination Symptoms
13%
Crohn's Disease Recurrence
13%
Colectomy
13%
Disease Location
13%
Endoscopic Recurrence
10%
Endoscopic Remission
10%
Anti-tumor Necrosis Factor (anti-TNF)
9%
Perianal Fistula
9%
Ulcerative Colitis Patient
9%
Clinical Outcomes
9%
Disease-associated
9%
Biologic Therapy
9%
Colitis
8%
Paddington
8%
Colon Resection
8%
Rutgeerts Score
8%
Colonic mucosa
8%
Interleukin-6
8%
High-grade Dysplasia
8%
Crohn's
8%
Mucosal Healing
8%
Mucosa-associated Microbiota
8%
Anti-drug Antibodies
8%
Confidence Interval
8%
Histological Score
8%
Colitis-associated Dysplasia
8%
Multicenter Cohort Study
8%
Meta-analysis
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
2-dose
7%
Clinical Course
7%
Endoscopic Diagnosis
7%